Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

New York University Hepatology Associates, New York

Einstein Medical Center, Philadelphia

Mercy Medical Center - Mcauley Plaza, Baltimore

UVA Health - University of Virginia Health System, Charlottesville

Gastrointestinal and Liver Specialists of Tidewater - Digestive and Liver Disease Specialists, Norfolk

Wake Forest University Baptist Medical Center, Winston-Salem

University of Florida Hepatology Research at CTRB, Gainesville

University of Miami Leonard M. Miller School of Medicine, Miami

Florida Research Institute, Lakewood Rch

Vanderbilt Digestive Disease Center, Nashville

University of Cincinnati, Cincinnati

Rapid City Medical Center, Rapid City

Springfield Clinic, Springfield

CommonSpirit Health Research Institute, Omaha

Pioneer Research Solutions, Houston

Peak Gastroenterology Associates Colorado Springs, Colorado Springs

UA Thomas D. Boyer Liver Institute, Tucson

Cedars-Sinai Medical Center, Los Angeles

Southern California Research Center - Coronado, Coronado

Velocity Clinical Research, Santa Ana

Liver Institute Northwest, Seattle

(G.I,R,I) GI Research Institute, Vancouver

Office of Dr. Gauthier, North Bay

Toronto General Hospital, Toronto

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal

306, Fukui

313, Fukuoka

305, Hamamatsu

308, Hirakata

309, Hiroshima

304, Isehara

303, Itabashi-ku

312, Kanazawa

307, Matsumoto

311, Ōmura

302, Sapporo

Teine Keijinkai Hospital, Sapporo

314, Yokohama